The TP Regimen in the Treatment of Early Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-11-23
Target enrollment:
Participant gender:
Summary
Previous studies have shown that TNBC is sensitive to DNA crosslinking-related
chemotherapeutic drugs such as platinum. However, there is a lack of large sample prospective
clinical data to compare the efficacy of TP and EC-T / TEC regimen in the neoadjuvant
chemotherapy of TNBC. Besides, the application of anthracycline drugs is limited to a certain
extent due to the cardiotoxicity. Based on the above evidence, the researchers hope to
explore a more effective and safer new adjuvant therapy for TNBC.